ATG-Fresenius S

DRUG2 trials

Sponsors

Neovii Biotech

Conditions

Graft vs Host DiseaseRenal Transplant Rejection

Phase 3

Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT)

CompletedNCT00655343

Neovii BiotechGraft vs Host Disease

Start: 2003-02-28End: 2009-03-31Updated: 2011-12-12

Efficacy and Safety of ATG-Fresenius Following a Renal Transplantation, Without Corticosteroids

TerminatedNCT01324934

Neovii BiotechRenal Transplant Rejection

Start: 2006-10-31End: 2011-01-31Updated: 2015-05-01

Related Papers

Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial.

2017-06-0180 citations

Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.

2009-08-18536 citations